Surmodics to Host Virtual Shareholder Meeting on February 17
Webcast is Live at 4:00 p.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 16, 2016--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification and in vitro diagnostic technologies to the healthcare
industry, announced today that it will host a live webcast of its Annual
Meeting of Shareholders on Wednesday, February 17, at 4:00 p.m. CT (5:00
Gary Maharaj, chief executive officer, and Sue Knight, chair of the
board, will provide a brief update on our business and key strategic
initiatives underway at the Company.
To access the webcast, go to www.virtualshareholdermeeting.com/SRDX16
five minutes prior to the start of the meeting to log in. In addition,
the Annual Meeting audio presentation will be archived on the Company’s
website following the meeting.
About Surmodics, Inc.
Surmodics partners with the world's leading and emerging medical device,
diagnostic and life sciences companies to develop and commercialize
innovative products designed to improve lives by enabling the detection
and treatment of disease. Surmodics’ mission is to be a trusted partner
to its customers by providing the most advanced surface modification
technologies and in vitro diagnostic chemical components that
help enhance the well-being of patients. The company’s core offerings
include surface modification coating technologies that impart lubricity,
prohealing and biocompatibility characteristics and components for in
vitro diagnostic test kits and microarrays. Surmodics’ strategy is
to build on the product and technical leadership within these fields,
and expand the core offerings to generate opportunities for longer term
sustained growth. Surmodics is headquartered in Eden Prairie, Minnesota.
For more information about the Company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the Company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160216005544/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000